Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pasithea Therapeutics (KTTA) Gains from Investment Securities (2021 - 2024)

Pasithea Therapeutics (KTTA) has disclosed Gains from Investment Securities for 4 consecutive years, with -$1406.0 as the latest value for Q4 2024.

  • Quarterly Gains from Investment Securities rose 97.62% to -$1406.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$51625.0 through Dec 2024, up 97.82% year-over-year, with the annual reading at -$115301.0 for FY2025, 248.19% down from the prior year.
  • Gains from Investment Securities hit -$1406.0 in Q4 2024 for Pasithea Therapeutics, down from $17649.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $880000.0 in Q2 2023 to a low of -$2.6 million in Q4 2021.
  • Historically, Gains from Investment Securities has averaged -$175691.1 across 4 years, with a median of $9304.5 in 2023.
  • Biggest YoY gain for Gains from Investment Securities was 139.22% in 2024; the steepest drop was 2882.92% in 2024.
  • Year by year, Gains from Investment Securities stood at -$2.6 million in 2021, then grew by 12.52% to -$2.3 million in 2022, then skyrocketed by 97.39% to -$59125.0 in 2023, then skyrocketed by 97.62% to -$1406.0 in 2024.
  • Business Quant data shows Gains from Investment Securities for KTTA at -$1406.0 in Q4 2024, $17649.0 in Q3 2024, and $35622.0 in Q2 2024.